Provided by Tiger Fintech (Singapore) Pte. Ltd.

Milestone Pharmaceuticals Inc.

1.28
+0.02001.59%
Post-market: 1.28-0.0007-0.05%19:50 EDT
Volume:1.44M
Turnover:1.82M
Market Cap:68.29M
PE:-1.92
High:1.32
Open:1.28
Low:1.21
Close:1.26
Loading ...
Nov 10, 2022

Major Issues Report

8-K - Current report
Oct 31, 2022

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Oct 24, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Oct 17, 2022

Major Issues Report

8-K - Current report
Sep 26, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Sep 20, 2022

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Aug 10, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 10, 2022

Major Issues Report

8-K - Current report
Jul 08, 2022

Major Issues Report

8-K - Current report
May 12, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Mar 24, 2022

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Mar 24, 2022

Major Issues Report

8-K - Current report
Mar 24, 2022

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 16, 2022

Major Issues Report

8-K - Current report
Feb 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 11, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 31, 2022

Correspondence

CORRESP [Cover] - Correspondence